ABSTRACT
Rationale Quantifying functional small airways disease (fSAD) requires additional expiratory computed tomography (CT) scan, limiting clinical applicability. Artificial intelligence (AI) could enable fSAD quantification from chest CT scan at total lung capacity (TLC) alone (fSADTLC).
Objectives To evaluate an AI model for estimating fSADTLC and study its clinical associations in chronic obstructive pulmonary disease (COPD).
Methods We analyzed 2513 participants from the SubPopulations and InteRmediate Outcome Measures in COPD Study (SPIROMICS). Using a subset (n = 1055), we developed a generative model to produce virtual expiratory CTs for estimating fSADTLC in the remaining 1458 SPIROMICS participants. We compared fSADTLC with dual volume, parametric response mapping fSADPRM. We investigated univariate and multivariable associations of fSADTLC with FEV1, FEV1/FVC, six-minute walk distance (6MWD), St. George’s Respiratory Questionnaire (SGRQ), and FEV1 decline. The results were validated in a subset (n = 458) from COPDGene study. Multivariable models were adjusted for age, race, sex, BMI, baseline FEV1, smoking pack years, smoking status, and percent emphysema.
Measurements and Main Results Inspiratory fSADTLC was highly correlated with fSADPRM in SPIROMICS (Pearson’s R = 0.895) and COPDGene (R = 0.897) cohorts. In SPIROMICS, fSADTLC was associated with FEV1 (L) (adj.β = −0.034, P < 0.001), FEV1/FVC (adj.β = −0.008, P < 0.001), SGRQ (adj.β = 0.243, P < 0.001), and FEV1 decline (mL / year) (adj.β = −1.156, P < 0.001). fSADTLC was also associated with FEV1 (L) (adj.β = −0.032, P < 0.001), FEV1/FVC (adj.β = −0.007, P < 0.001), SGRQ (adj.β = 0.190, P = 0.02), and FEV1 decline (mL / year) (adj.β = - 0.866, P = 0.001) in COPDGene. We found fSADTLC to be more repeatable than fSADPRM with intraclass correlation of 0.99 (95% CI: 0.98, 0.99) vs. 0.83 (95% CI: 0.76, 0.88).
Conclusions Inspiratory fSADTLC captures small airways disease as reliably as fSADPRM and is associated with FEV1 decline.
Funding Source This work was supported by NHLBI grants R01 HL142625, U01 HL089897 and U01 HL089856, by NIH contract 75N92023D00011, and by a grant from The Roy J. Carver Charitable Trust (19-5154). The COPDGene study (NCT00608764) has also been supported by the COPD Foundation through contributions made to an Industry Advisory Committee that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion.
Competing Interest Statement
APC has received grants from the NIH and consulting fees from GlaxoSmithKline (GSK), AstraZeneca, and Elli Lilly. IZB received grants from Theravance and Viatris, Aerogen, and Takeda; and consulting fees from AstraZeneca, Sanofi/Regeneron, Grifols, Verona Pharma, Inhibrx, and Takeda. RGB has received grants from the NIH-NHLBI, COPD Foundation, Foundation for the NIH, and American Lung Association. CBC has received grants from the NIH-NHLBI, COPD Foundation, and Foundation for the NIH; royalties from the Cambridge University Press, payments and honoraria from GSK, Chulalongkorn University in Bangkok, AstraZeneca, and fees from NUVAIRA, Horizon Therapeutics, MGC Diagnostics, Chiesi, Herbalife Nutrition Institute, Respiree, Aer Therapeutics, Genentech, RS Biotherapeutics, and Verona. CJG is co-inventor and patent holder of PRM, which the University of Michigan has licensed to Imbio, LLC. MKH reports personal fees from GSK, AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Novartis, PulmonX, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarean, Regeneron, Amgen, UpToDate, Altesa Biopharma, Medscape, NACE, MDBriefcase and Integrity. She has received either in kind research support or funds paid to the institution from the NIH, Novartis, Sunovion, NUVAIRA, Sanofi, AstraZeneca, Boehringer Ingelheim, Gala Therapeutics, Biodesix, the COPD Foundation and the American Lung Association. She has participated in Data Safety Monitoring Boards for Novartis and Medtronic with funds paid to the institution. She has received stock options from Meissa Vaccines and Altesa Biopharma. JLC has received grants from the NIH/NHLBI, COPD Foundation, NIH/NIAID, Department of Veterans Affairs, and Department of Defense; and consulting fees from CSL Behring, LLC., AstraZeneca and Novartis. NNH has received grants from the NIH, COPD Foundation, AstraZeneca, and GSK; and fees from AstraZeneca, GSK, and Regeneron. JAH has received grants from the NIH, COPD Foundation, American Lung Association, and US Patient Centered Outcomes Research Institute; and consulting fees from AstraZeneca, CereVu Medical, BData, Inc., American Board of Internal Medicine, DynaMed; payments from University of Chicago, and American Academy of Asthma, Allergy, and Immunology. MGM has received grants from the NIH and NHLBI. FJM has received grants from NHLBI, AstraZeneca, Chiesi, GlaxoSmithKline, and Sanofi/Regeneron; fees for consultancy work from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, LLC., Gala, GSK, Novartis, Polarean, PulmonX, Sanofi/Regeneron, Sunovion, Teva, Theravance & Viatris, and Verona; payment or honoraria for lectures, presentations, speaking, bureaus, manuscript writing, or educational events from UpToDate; and is a member of the data safety monitoring board of MedTronic. JO has received grants from Teva, Boehringer Ingelheim; consulting fees from AstraZeneca, Cello Health Bioconsulting, Guidepost, Health Advances, Verona, Adept Field Solutions; payments from AstraZeneca, Cadent Medical Communications, and various law firms for expert testimony. RP has received grants from the NIH/NHLBI, COPD Foundation, Foundation for the NIH, Department of Veterans Affairs, and Partner Therapeutics; and consulting fees from Partner Therapeutics. SPB has received grants from the NIH/NHLBI, royalties from Elsevier, consulting fees from Boehringer Ingelheim and Sanofi/Regeneron, payments from IntegrityCE, and NIH. EAH has received grants from the NIH, royalties or licensing fees from VIDA Diagnostics, and is the founder and shareholder of VIDA Diagnostics. JMR received grants from the NIH/NHLBI, Carver Charitable Trust, royalties from VIDA Diagnostics, payments from Auris Health, Inc., and is a shareholder at VIDA Diagnostics.
Funding Statement
This work was supported by NHLBI grants R01 HL142625, U01 HL089897 and U01 HL089856, by NIH contract 75N92023D00011, and by a grant from The Roy J. Carver Charitable Trust (19-5154). The COPDGene study (NCT00608764) has also been supported by the COPD Foundation through contributions made to an Industry Advisory Committee that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study uses data from two large cohorts, SPIROMICS and COPDGene. Both studies conducted according to the principles of the Helsinki accord. Written informed consent for both studies was provided by all participants, and the protocols were approved by the Institutional Review Boards (IRBs) of each participating study center.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵Ψ Muhammad F. A. Chaudhary is now at the Center for Lung Analytics and Imaging Research (CLAIR) at The University of Alabama at Birmingham. This study was conducted when he was at The Roy J. Carver Department of Biomedical Engineering at The University of Iowa.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.